Ilan Zipkin
Vorstandsvorsitzender bei Anteris Bio, Inc.
Ursprung des Netzwerks ersten Grades von Ilan Zipkin
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Takeda Ventures, Inc.
Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California.
9
| Subsidiary | Investment Managers | 9 |
Anteris Bio, Inc.
Anteris Bio, Inc. Pharmaceuticals: MajorHealth Technology Anteris Bio, Inc. develops therapies for the treatment of renal disease. The company is based in Oakland, CA. The CEO of the company is Ilan Zipkin.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Via Nova Therapeutics, Inc.
Via Nova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Via Nova Therapeutics, Inc. is a company that aims to discover and develop safe and effective therapies for viral diseases with inadequate treatments. The company is based in Oakland, CA. Via Nova's pipeline includes four programs targeting influenza, human rhinovirus, polyomavirus, and adenovirus. The company is committed to advancing this initial pipeline with additional discovery efforts to follow. Via Nova believes that the recent expansion of point-of-care testing and telemedicine driven by the COVID-19 pandemic will transform the diagnostic landscape, allowing early recognition of all the important respiratory viruses. The company was founded in August 2021 and has in-licensed antiviral programs from RTIs. The CEO of the company is Donald Emil Ganem.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Ilan Zipkin
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
ALZA CORPORATION | Pharmaceuticals: Major | Corporate Officer/Principal | |
ICL GROUP LTD | Chemicals: Agricultural | Director/Board Member | |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member | |
FORMA THERAPEUTICS HOLDINGS, INC. | Pharmaceuticals: Major | Director/Board Member | |
BioMotiv LLC
BioMotiv LLC BiotechnologyHealth Technology BioMotiv LLC operates as a research institution in the field of therapeutics. It focuses in disease areas and classes of therapeutics such as small molecules, antibodies, proteins, and nucleotides. The company was founded on September 10, 2012 and is headquartered in Cleveland, OH. | Biotechnology | Director/Board Member | |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Hospital/Nursing Management | Director/Board Member | |
NOVARTIS AG | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
The Trustees of Columbia University in The City of New York | College/University | Graduate Degree | |
University of Bath | College/University | Undergraduate Degree | |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
University of Oxford | College/University | Doctorate Degree | |
XENOPORT, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Massachusetts Institute of Technology | College/University | Doctorate Degree Graduate Degree | |
Yale University | College/University | Undergraduate Degree Undergraduate Degree | |
Santa Clara University | College/University | Undergraduate Degree | |
INSEAD | College/University | Masters Business Admin | |
University of California, Berkeley | College/University | Masters Business Admin Undergraduate Degree | |
Tel-Aviv University
Tel-Aviv University Other Consumer ServicesConsumer Services Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel. | College/University | Masters Business Admin | |
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz. | Investment Managers | Private Equity Investor | |
University College London | College/University | Doctorate Degree | |
University of Tokyo | College/University | Doctorate Degree Graduate Degree | |
Nagoya University | College/University | Doctorate Degree | |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Biotechnology | Corporate Officer/Principal | |
ENZYMOTEC LTD. | Biotechnology | Director/Board Member | |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Investment Managers | Private Equity Investor | |
Propharma Partners International, Inc. | Corporate Officer/Principal | ||
University of Haifa | College/University | Undergraduate Degree | |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Medical Specialties | Director/Board Member | |
Adicet Therapeutics, Inc.
Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Pharmaceuticals: Major | Director/Board Member | |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Investment Managers | Director/Board Member | |
Fore Biotherapeutics, Inc.
Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Director/Board Member | |
BiomX Ltd.
BiomX Ltd. Pharmaceuticals: MajorHealth Technology BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ImmPACT-Bio Ltd.
ImmPACT-Bio Ltd. BiotechnologyHealth Technology ImmPACT-Bio Ltd. develops therapies to treat cancer. Its chimeric antigen receptor T-cell (CAR-T) therapy addresses the need to differentiate cancerous from non-cancerous tissues. The company was founded by Gideon Gross in April 2017 and is headquartered in Nes Ziona, Israel. | Biotechnology | Director/Board Member | |
DJS Antibodies Ltd.
DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | Biotechnology | Chairman | |
Scioto Biosciences, Inc.
Scioto Biosciences, Inc. BiotechnologyHealth Technology Scioto Biosciences, Inc. operates as a preclinical stage company. It develops therapies to transform the delivery of microbiome therapeutics. The firm?s platform enhances probiotics that are used for diabetes, neurological disorders, gastrointestinal health and alternatives to in-feed antibiotics. The company was founded by Joseph P. Trebley, Jim Schulz, Goodman Steve, Lauren O. Bakaletz, Michael Bailey and Gail E. Besner in May 2017 and is headquartered in Indianapolis, IN. | Biotechnology | Director/Board Member | |
Imidomics, Inc.
Imidomics, Inc. BiotechnologyHealth Technology Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves. | Biotechnology | Chief Executive Officer | |
Redona Therapeutics, Inc.
Redona Therapeutics, Inc. BiotechnologyHealth Technology Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA. | Biotechnology | Director/Board Member | |
Aditum Bio Fund 1 LP
Aditum Bio Fund 1 LP Investment ManagersFinance Aditum Bio Fund 1 LP specializes in acquiring and developing pharmaceutical assets. The company is headquartered in San Mateo, CA. | Investment Managers | Director/Board Member Director/Board Member | |
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | Investment Managers | Chief Executive Officer | |
HatchBox Bioconsulting LLC
HatchBox Bioconsulting LLC Miscellaneous Commercial ServicesCommercial Services HatchBox Bioconsulting LLC provides life science advisory services. | Miscellaneous Commercial Services | Private Equity Investor | |
Nautic & Art, Inc.
Nautic & Art, Inc. Recreational ProductsConsumer Durables Nautic & Art, Inc. manufactures professional inflatable boats made in military-grade hypalon. It specializes in search and rescue and special intervention like the army, fire department, police department, and coast guard. the company is headquartered in Windsor, Canada. | Recreational Products | Director/Board Member | |
Alsa Management Services Ltd
Alsa Management Services Ltd Investment ManagersFinance Alsa Management Services Ltd (ALSA Ventures) is a venture capital firm founded in 2018. The firm is headquartered in London, United Kingdom. | Investment Managers | Chief Investment Officer | |
Geneception, Inc.
Geneception, Inc. BiotechnologyHealth Technology Geneception, Inc. provides healthcare services. The company is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Arjuna Therapeutics
Arjuna Therapeutics Medical/Nursing ServicesHealth Services Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge. | Medical/Nursing Services | Director/Board Member | |
Versanis Bio, Inc.
Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Biotechnology | Director/Board Member Director/Board Member | |
Teres Bio, Inc.
Teres Bio, Inc. Pharmaceuticals: MajorHealth Technology Teres Bio, Inc. operates as a clinical stage life sciences company. It translates discoveries in inflammatory pathways into novel, topical therapies for atopic dermatitis and plaque psoriasis skin diseases. The company is headquartered in Oakland, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
BioNeex, Inc.
BioNeex, Inc. Packaged SoftwareTechnology Services BioNeex, Inc. is an American company located in Syracuse, NY, that operates as a drug development platform. It was founded by Smbat Rafayelyan and Tigran Rafayelyan. Smbat Rafayelyan has been the CEO since 2018. The company says this about itself: BioNeex is the first R&D open exchange platform in the biopharma industry, facilitating licensing and co-development partnerships for preclinical and clinical-stage drug candidates between biotech, biopharma companies and research institutions. Data posted on the drug candidate marketplace is listed by biotech, biopharma companies, and research institutions, enabling potential licensing and co-development partners as well as investors to contact them directly with one click. | Packaged Software | Director/Board Member | |
Vantage Biosciences Ltd.
Vantage Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Vantage Biosciences Ltd. develops drugs for diabetic eye disease. The British company was founded by Andre Badalyan, Katie Sunnucks, Graeme R. Martin, Alek Safarian. | Pharmaceuticals: Major | Founder |
Statistik
International
Vereinigte Staaten | 29 |
Israel | 8 |
Vereinigtes Königreich | 7 |
Japan | 4 |
Schweiz | 3 |
Sektoral
Health Technology | 24 |
Consumer Services | 13 |
Finance | 8 |
Health Services | 3 |
Consumer Non-Durables | 2 |
Operativ
Director/Board Member | 58 |
Corporate Officer/Principal | 20 |
Private Equity Investor | 14 |
Independent Dir/Board Member | 10 |
Chief Executive Officer | 9 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Joseph Jimenez | 32 |
Mark Fishman | 17 |
Michal Silverberg | 17 |
Karen Ho Hong | 16 |
Graeme Martin | 15 |
Juan M. E. Harrison | 9 |
Benjamine Liu | 7 |
Yuji Iizawa | 3 |
Hiroya Muranishi | 3 |
Hiroyuki hata | 3 |
Etsuya Matsutani | 2 |
Shingo Makino | 1 |
Donald Emil Ganem | 1 |
- Börse
- Insiders
- Ilan Zipkin
- Unternehmensverbindungen